The handling of the H1N1 pandemic by the World Health Organization (WHO), European Union agencies and national governments led to a 'waste of large sums of public money, and unjustified scares and fears about the health risks faced by the European public,' according to a report by the Social, Health and Family Affairs Committee of the Parliamentary Assembly of the Council of Europe (PACE) made public last week in Paris, France.
The report is just another criticism of the WHO's handling of the pandemic. As reported yesterday (The Pharma Letter June 7), the British Medical Journal, in a joint enquiry with the Bureau of Investigative Journalism, unveiled conflicts of interest among the agency's expert scientists, finding that three scientists involved in putting together the 2004 guidance had previously been paid by drug majors Roche or GlaxoSmithKline for lecturing and consultancy work as well as being involved in research for the firms.
The PACE report, prepared by European Member of Parliament Paul Flynn (UK, SOC) and approved by the committee ahead of a plenary debate at the end of this month, says there was 'overwhelming evidence that the seriousness of the pandemic was vastly overrated by WHO,' resulting in a distortion of public health priorities.' The PACE investigation was triggered by claims in January by the health committee's then-chairman, Wolfgang Wodarg, of undue industry influence helping to trigger the 'false pandemic' (TPLs passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze